134 related articles for article (PubMed ID: 11960724)
41. Feasibility of photofrin II as a radiosensitizing agent in solid tumors--preliminary results.
Schaffer M; Ertl-Wagner B; Schaffer PM; Kulka U; Jori G; Wilkowski R; Hofstetter A; Dühmke E
Onkologie; 2006 Nov; 29(11):514-9. PubMed ID: 17068386
[TBL] [Abstract][Full Text] [Related]
42. Tumor delivery of Photofrin® by PLL-g-PEG for photodynamic therapy.
Kano A; Taniwaki Y; Nakamura I; Shimada N; Moriyama K; Maruyama A
J Control Release; 2013 May; 167(3):315-21. PubMed ID: 23454112
[TBL] [Abstract][Full Text] [Related]
43. Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Dougherty TJ
Lasers Surg Med; 2006 Jun; 38(5):439-44. PubMed ID: 16634075
[TBL] [Abstract][Full Text] [Related]
44. Tumor blood-flow changes following protoporphyrin IX-based photodynamic therapy in mice and humans.
Herman MA; Fromm D; Kessel D
J Photochem Photobiol B; 1999; 52(1-3):99-104. PubMed ID: 10643075
[TBL] [Abstract][Full Text] [Related]
45. A novel homogeneous irradiation fiber probe for whole bladder wall photodynamic therapy.
Miyazaki K; Morimoto Y; Nishiyama N; Maekawa Y; Hu WZ; Nakatate K; Kaneda K; Shinomiya N; Kataoka K
Lasers Surg Med; 2012 Jul; 44(5):413-20. PubMed ID: 22367582
[TBL] [Abstract][Full Text] [Related]
46. Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma.
Peng Q; Moan J; Ma LW; Nesland JM
Cancer Res; 1995 Jun; 55(12):2620-6. PubMed ID: 7780978
[TBL] [Abstract][Full Text] [Related]
47. Post-acute response of 9L gliosarcoma to Photofrin-mediated PDT in athymic nude mice.
Zhang X; Jiang F; Kalkanis SN; Zhang Z; Hong X; Yang H; Chopp M
Lasers Med Sci; 2007 Nov; 22(4):253-9. PubMed ID: 17505777
[TBL] [Abstract][Full Text] [Related]
48. Subcellular localization of Photofrin and aminolevulinic acid and photodynamic cross-resistance in vitro in radiation-induced fibrosarcoma cells sensitive or resistant to photofrin-mediated photodynamic therapy.
Wilson BC; Olivo M; Singh G
Photochem Photobiol; 1997 Jan; 65(1):166-76. PubMed ID: 9066298
[TBL] [Abstract][Full Text] [Related]
49. Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers.
Lilge L; Wilson BC
J Clin Laser Med Surg; 1998 Apr; 16(2):81-91. PubMed ID: 9663099
[TBL] [Abstract][Full Text] [Related]
50. Photodynamic therapy using Photofrin in combination with buthionine sulfoximine (BSO) to treat 9L gliosarcoma in rat brain.
Jiang F; Lilge L; Belcuig M; Singh G; Grenier J; Li Y; Chopp M
Lasers Surg Med; 1998; 23(3):161-6. PubMed ID: 9779650
[TBL] [Abstract][Full Text] [Related]
51. Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy.
Pandey RK; Bellnier DA; Smith KM; Dougherty TJ
Photochem Photobiol; 1991 Jan; 53(1):65-72. PubMed ID: 2027908
[TBL] [Abstract][Full Text] [Related]
52. In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors.
Zupkó I; Kamuhabwa AR; D'Hallewin MA; Baert L; De Witte PA
Int J Oncol; 2001 May; 18(5):1099-105. PubMed ID: 11295062
[TBL] [Abstract][Full Text] [Related]
53. Effect of drug-light interval on the mode of action of Photofrin photodynamic therapy in a mouse tumor model.
Li LB; Luo RC
Lasers Med Sci; 2009 Jul; 24(4):597-603. PubMed ID: 18936869
[TBL] [Abstract][Full Text] [Related]
54. Photodynamic therapy with 5-aminolaevulinic acid-induced porphyrins of an amelanotic melanoma in vivo.
Abels C; Fritsch C; Bolsen K; Szeimies RM; Ruzicka T; Goerz G; Goetz AE
J Photochem Photobiol B; 1997 Aug; 40(1):76-83. PubMed ID: 9301046
[TBL] [Abstract][Full Text] [Related]
55. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
[TBL] [Abstract][Full Text] [Related]
56. Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats.
Van Hillegersberg R; Van den Berg JW; Kort WJ; Terpstra OT; Wilson JH
Gastroenterology; 1992 Aug; 103(2):647-51. PubMed ID: 1386052
[TBL] [Abstract][Full Text] [Related]
57. Photobleaching kinetics of Photofrin in vivo and in multicell tumour spheroids indicate two simultaneous bleaching mechanisms.
Finlay JC; Mitra S; Patterson MS; Foster TH
Phys Med Biol; 2004 Nov; 49(21):4837-60. PubMed ID: 15584523
[TBL] [Abstract][Full Text] [Related]
58. Observations in studies of quantitative kinetics of tritium labelled hematoporphyrin derivatives (HpDI and HpDII) in the normal and neoplastic rat brain model.
Little FM; Gomer CJ; Hyman S; Apuzzo ML
J Neurooncol; 1984; 2(4):361-70. PubMed ID: 6241630
[TBL] [Abstract][Full Text] [Related]
59. Photodynamic therapy of U87 human glioma in nude rat using liposome-delivered photofrin.
Jiang F; Lilge L; Grenier J; Li Y; Wilson MD; Chopp M
Lasers Surg Med; 1998; 22(2):74-80. PubMed ID: 9484699
[TBL] [Abstract][Full Text] [Related]
60. Quantum yields and kinetics of the photobleaching of hematoporphyrin, Photofrin II, tetra(4-sulfonatophenyl)-porphine and uroporphyrin.
Spikes JD
Photochem Photobiol; 1992 Jun; 55(6):797-808. PubMed ID: 1409888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
